FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177285706> ?p ?o ?g. }

• W3177285706 endingPage "304" @default.
• W3177285706 startingPage "304" @default.
• W3177285706 abstract "Escherichia coli is a major etiologic agent of cow mastitis, a condition that results in huge economic losses. There is a lack of an oral vaccine for cow mastitis. Previous studies have confirmed that the outer membrane protein A (OmpA) of E. coli is immunogenic and can be used for vaccine design. In the present study, OmpA was encapsulated into nanoparticles (NP-OmpA) for an oral vaccine for cow mastitis. Methods: OmpA was purified with Ni-NTA flow resin and encapsulated with chitosan (CS) to prepare NP-OmpA nanoparticles. The gastrointestinal tract was simulated in vitro (PBS, pH 1.2) to measure the protein release rate. The optimal preparation conditions for NP-OmpA were determined by analyzing the concentrations of OmpA and CS, magnetic mixing speed, mixing time, and the ratio of tripolyphosphate (TPP)/CS (w/w). NP-OmpA safety was assessed by function factors and histopathological examination of livers and kidneys. The immune activity of NP-OmpA was determined using qRT-PCR to assess immune-related gene expression, leukocyte phagocytosis of Staphylococcus aureus, ELISA to evaluate antiserum titer and immune recognition of E. coli, and the organ index. The immune protection function of NP-OmpA was assessed by the protection rate of NP-OmpA to E. coli in mice, qRT-PCR for inflammation-related gene expression, assay kits for antioxidant factors, and visceral injury in the histopathological sections. Results: NP-OmpA nanoparticles had a diameter of about 700 nm, loading efficiency (LE) of 79.27%, and loading capacity (LC) of 20.31%. The release rate of NP-OmpA (0~96 h) was less than 50% in vitro. The optimal preparation conditions for NP-OmpAs were OmpA protein concentration of 2 mg/mL, CS concentration of 5 mg/mL, TPP/CS (w/w) of 1:1, magnetic mixing speed of 150 r/min, and mixing time of 15 min. Histopathological sections and clinical analytes of uric acid (UA), creatinine (Cr), alanine aminotransferase (ALT), aspartate transaminase (AST), catalase (CAT), glutathione (GSH), and malondialdehyde (MDA) showed NP-OmpA did not damage mice livers or kidneys. NP-OmpA could enhance the immune-related gene expression of IFN-γ and HSP70 in the spleen, liver, and kidney and the leukocyte phagocytosis of S. aureus. The antiserum titer (1:3200) was obtained from mice immunized with NP-OmpA, which had an immune recognition effect to E. coli. The immune protection rate of NP-OmpA was 71.43% (p < 0.05) to E. coli. NP-OmpA could down-regulate the inflammation-related gene expression of TNF-a, IL-6, and IL-10 in the spleen, liver, and kidney, and the antioxidant factors MDA and SOD in the liver, and reduce injury in the liver and kidney of mice induced by E. coli. Conclusions: A novel NP-OmpA nanoparticle was encapsulated, and the optimal preparation conditions were determined. The NP-OmpA was safe and had good immune functions. They are expected to induce a response that resists infection with the major etiologic agent (E. coli) of cow mastitis." @default.
• W3177285706 created "2021-07-05" @default.
• W3177285706 creator A5005460814 @default.
• W3177285706 creator A5021165680 @default.
• W3177285706 creator A5047526614 @default.
• W3177285706 creator A5051381411 @default.
• W3177285706 creator A5062601842 @default.
• W3177285706 creator A5063253432 @default.
• W3177285706 creator A5070059174 @default.
• W3177285706 creator A5075608733 @default.
• W3177285706 creator A5082213642 @default.
• W3177285706 date "2021-03-23" @default.
• W3177285706 modified "2023-09-28" @default.
• W3177285706 title "Synthesis of Escherichia coli OmpA Oral Nanoparticles and Evaluation of Immune Functions against the Major Etiologic Agent of Cow Mastitis" @default.
• W3177285706 cites W1208483527 @default.
• W3177285706 cites W1977245369 @default.
• W3177285706 cites W2159584001 @default.
• W3177285706 cites W2552375428 @default.
• W3177285706 cites W2736768972 @default.
• W3177285706 cites W2765986387 @default.
• W3177285706 cites W2768945827 @default.
• W3177285706 cites W2774917626 @default.
• W3177285706 cites W2789310161 @default.
• W3177285706 cites W2799907578 @default.
• W3177285706 cites W2801023971 @default.
• W3177285706 cites W2803499852 @default.
• W3177285706 cites W2805370601 @default.
• W3177285706 cites W2807718594 @default.
• W3177285706 cites W2811375075 @default.
• W3177285706 cites W2883017015 @default.
• W3177285706 cites W2885131611 @default.
• W3177285706 cites W2903766627 @default.
• W3177285706 cites W2906884347 @default.
• W3177285706 cites W2946058559 @default.
• W3177285706 cites W2947364715 @default.
• W3177285706 cites W2949532620 @default.
• W3177285706 cites W2951966558 @default.
• W3177285706 cites W2967164097 @default.
• W3177285706 cites W2969494195 @default.
• W3177285706 cites W2969639077 @default.
• W3177285706 cites W2971135024 @default.
• W3177285706 cites W2986156039 @default.
• W3177285706 cites W2993856664 @default.
• W3177285706 cites W2996298773 @default.
• W3177285706 cites W2997933217 @default.
• W3177285706 cites W3006050541 @default.
• W3177285706 cites W3012561729 @default.
• W3177285706 cites W3015980338 @default.
• W3177285706 cites W3032002363 @default.
• W3177285706 cites W805811693 @default.
• W3177285706 doi "https://doi.org/10.3390/vaccines9030304" @default.
• W3177285706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8005184" @default.
• W3177285706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33807110" @default.
• W3177285706 hasPublicationYear "2021" @default.
• W3177285706 type Work @default.
• W3177285706 sameAs 3177285706 @default.
• W3177285706 citedByCount "8" @default.
• W3177285706 countsByYear W31772857062021 @default.
• W3177285706 countsByYear W31772857062022 @default.
• W3177285706 countsByYear W31772857062023 @default.
• W3177285706 crossrefType "journal-article" @default.
• W3177285706 hasAuthorship W3177285706A5005460814 @default.
• W3177285706 hasAuthorship W3177285706A5021165680 @default.
• W3177285706 hasAuthorship W3177285706A5047526614 @default.
• W3177285706 hasAuthorship W3177285706A5051381411 @default.
• W3177285706 hasAuthorship W3177285706A5062601842 @default.
• W3177285706 hasAuthorship W3177285706A5063253432 @default.
• W3177285706 hasAuthorship W3177285706A5070059174 @default.
• W3177285706 hasAuthorship W3177285706A5075608733 @default.
• W3177285706 hasAuthorship W3177285706A5082213642 @default.
• W3177285706 hasBestOaLocation W31772857061 @default.
• W3177285706 hasConcept C104317684 @default.
• W3177285706 hasConcept C147483822 @default.
• W3177285706 hasConcept C185592680 @default.
• W3177285706 hasConcept C203014093 @default.
• W3177285706 hasConcept C2776344049 @default.
• W3177285706 hasConcept C2779489039 @default.
• W3177285706 hasConcept C523546767 @default.
• W3177285706 hasConcept C54355233 @default.
• W3177285706 hasConcept C547475151 @default.
• W3177285706 hasConcept C55493867 @default.
• W3177285706 hasConcept C86803240 @default.
• W3177285706 hasConcept C8891405 @default.
• W3177285706 hasConcept C89423630 @default.
• W3177285706 hasConcept C91523082 @default.
• W3177285706 hasConceptScore W3177285706C104317684 @default.
• W3177285706 hasConceptScore W3177285706C147483822 @default.
• W3177285706 hasConceptScore W3177285706C185592680 @default.
• W3177285706 hasConceptScore W3177285706C203014093 @default.
• W3177285706 hasConceptScore W3177285706C2776344049 @default.
• W3177285706 hasConceptScore W3177285706C2779489039 @default.
• W3177285706 hasConceptScore W3177285706C523546767 @default.
• W3177285706 hasConceptScore W3177285706C54355233 @default.
• W3177285706 hasConceptScore W3177285706C547475151 @default.
• W3177285706 hasConceptScore W3177285706C55493867 @default.
• W3177285706 hasConceptScore W3177285706C86803240 @default.
• W3177285706 hasConceptScore W3177285706C8891405 @default.
• W3177285706 hasConceptScore W3177285706C89423630 @default.

• next